AlphAIalphai — Financial news for AI agents
BenzingaOCT 312 min read$ITRI

This Itron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Comcast (NASDAQ:CMCSA), Bicycle Therapeutics (NASDAQ:BCYC)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Original reporting
Benzinga · Avi Kapoor
Published Oct 31, 2025, 12:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 31, 2025, 1:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
This Itron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Comcast (NASDAQ:CMCSA), Bicycle Therapeutics (NASDAQ:BCYC) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$ITRINeutralMed
01

Why it matters

While downgrades can lead to short-term declines, the mixed sentiment and technical support levels suggest limited downside for some stocks.

02

Market read

The news has moderate relevance for traders focusing on the impacted sectors, with limited broader market implications.

03

What to watch

Broader market conditions and upcoming earnings reports could influence stock movements independently of analyst ratings.

Timing: Immediate to short-term

Background

Recent analyst downgrades on key stocks in Life Sciences and Technology sectors have caused some concern among traders.

Company-level read

Ticker impact

$ITRINeutralMedium confidence
Context

High relevance due to recent analyst downgrade and somewhat bullish sentiment.

Expected impact

Moderate short-term decline followed by stabilization.

Evidence & confidence

The downgrade indicates caution, but the mixed sentiment and lack of technical breakdowns suggest limited downside.

$CCZNeutralLow confidence
Context

Low relevance; neutral sentiment and no recent analyst activity.

Expected impact

Likely negligible price movement.

Evidence & confidence

Relevance score is low; no significant analyst activity or sentiment change.

$BCYCBullishMedium confidence
Context

Moderate relevance; somewhat bullish sentiment but recent analyst downgrade.

Expected impact

Possible short-term increase, then consolidation.

Evidence & confidence

Mixed signals imply cautious optimism; technical support levels may hold.

Market effects

Sector

Potential sector-wide caution in Life Sciences and Technology sectors due to analyst downgrades.

Regional

Limited regional impact; news pertains mainly to US-listed companies.

Global

Low; specific to individual companies with limited global influence.

Counterpoint

What could challenge this read

The analyst downgrade may be overreacting; fundamentals could support the stocks, leading to a quick recovery.

Key entities

  • Author
    Avi Kapoor

    Financial analyst and writer at Benzinga.

  • Source
    Benzinga

    Financial news and analysis platform.

Read at source← All news

Related articles

AUG 6
$ITRIMedAI 8/10

Why Shares of Itron Stock Jumped 17.4% This Week

Itron shares rose about 17% this week after the company reported strong Q2 results and raised full-year guidance, according to S&P Global Market Intelligence. Itron posted non-GAAP EPS of $1.59 versus $1.29 expected and cited demand for grid stability tied to AI infrastructure build-out. Full-year EPS guidance was raised to $6.40 at the midpoint.

aol.com4 min
JUL 31
$ITRIMed

Why Shares of Itron Stock Jumped 17.4% This Week

Itron (NASDAQ: ITRI) shares rose about 17.4% this week, after the utility technology company reported strong Q2 results and raised full-year guidance, according to S&P Global Market Intelligence. Non-GAAP EPS was $1.59 versus $1.29 expected. Full-year EPS guidance was raised to $6.40 at the midpoint.

yahoo.com4 min
JUL 30
$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).

finanznachrichten.de6 min
JUL 30
$BCYCMed

BICYCLE THERAPEUTICS PLC (BCYC): Results of Operations and Financial Condition

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621593d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology thera

SEC EDGAR 8-K6 min
JUL 30
$ITRIMedAI 8/10

Itron Q2 Earnings Call Highlights

Itron (NASDAQ:ITRI) reported Q2 GAAP net income of $53M, or $1.19/diluted share, versus $68M a year earlier. Non-GAAP operating income rose 8% to $89M and adjusted EBITDA rose 8% to $97M. Q2 revenue by segment: Device Solutions $111M, Networked Solutions $339M, Outcomes $96M, Resiliency Solutions about $16M. Free cash flow was $81M. Backlog was $4.4B. Itron raised full-year non-GAAP EPS to $6.30-$6.50 and narrowed revenue to $2.37B-$2.41B.

yahoo.com6 min